Emerald Cloud Lab vs Schrödinger

Side-by-side comparison of AI visibility scores, market position, and capabilities

Schrödinger leads in AI visibility (74 vs 54)
Emerald Cloud Lab logo

Emerald Cloud Lab

ChallengerLife Sciences & BioTech

Remote Laboratory Automation

Emerald Cloud Lab offers a fully remote, cloud-controlled laboratory with 200+ instrument models; ~$15M ARR as of 2025 with labs in the U.S. and expanded facilities in Austin and Pittsburgh.

AI VisibilityBeta
Overall Score
C54
Category Rank
#37 of 198
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
48
Gemini
55

About

Emerald Cloud Lab (ECL) is a biotechnology infrastructure company that enables scientists to conduct real wet-lab experiments entirely remotely through a cloud-based interface. Founded as a spin-out of Emerald Therapeutics, ECL operates physical laboratories stocked with over 200 instrument models — including liquid handlers, mass spectrometers, and genomics tools — that researchers control through its unified Command Center software. Scientists can design, execute, and analyze experiments without ever entering a physical lab, democratizing access to advanced instrumentation that would otherwise require millions in capital expenditure.

Full profile
Schrödinger logo

Schrödinger

LeaderLife Sciences & BioTech

Computational Drug Discovery

Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.

AI VisibilityBeta
Overall Score
B74
Category Rank
#1 of 198
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
80
Gemini
75

About

Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.

Full profile

AI Visibility Head-to-Head

54
Overall Score
74
#37
Category Rank
#1
78
AI Consensus
84
stable
Trend
stable
54
ChatGPT
74
48
Perplexity
80
55
Gemini
75
48
Claude
74
48
Grok
78

Key Details

Category
Remote Laboratory Automation
Computational Drug Discovery
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Schrödinger
Computational Drug Discovery

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.